AI assistant
Q32 Bio Inc. — Director's Dealing 2023
Feb 27, 2023
34891_dirs_2023-02-27_c6b8b968-5010-4f99-a102-fa8e14c669de.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2023-02-23
Reporting Person: Seymour Albert (Director, See Remarks)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-23 | Employee Stock Option (Right to Buy) | $1.60 | A | 632000 | Acquired | 2033-02-23 | Common Stock (632000) | Direct |
| 2023-02-23 | Restricted Stock Units | $ | A | 105000 | Acquired | Common Stock (105000) | Direct |
Footnotes
F1: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023.
F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.
F3: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026.